DOCTOR FUNGUS
CME program -
"Treating Fungal Infections: Echinocandins, novel antifungals"

Lectures from the symposium at Focus On Fungal Infections 13 - March 20, 2003 Maui, Hawaii		  
Disclosure of commercial interests

John R. Graybill, M.D.
  • Merck1.2.3
  • Schering Plough1
  • Fujisawa1,2
  • Versicor2
1=Grant/research support | 2=Consultant
3=Speaker's bureau | 4=Stock shareholder
5=Other support


Peter G. Pappas, M.D.
  • Merck1,3
  • Pfizer1,3
  • Schering Plough1
  • Fujisawa1,3
1=Grant/research support | 2=Consultant
3=Speaker's bureau | 4=Stock shareholder
5=Other support


John R. Perfect, M.D.
  • Merck1
  • Fujisawa1
  • Schering Plough1
  • Pfizer1
  • Elan/Enzon1
1=Grant/research support | 2=Consultant
3=Speaker's bureau | 4=Stock shareholder
5=Other support

Michael A. Pfaller, M.D.
  • Pfizer1,2,3
  • BMS1,2
  • Merck1,2,3
  • Schering Plough1
  • Versicor1,2
1=Grant/research support | 2=Consultant
3=Speaker's bureau | 4=Stock shareholder
5=Other support

Jack D. Sobel, M.D.
  • Pfizer1,3
  • Merck1,3
  • 3M1,3
upTop of page
  
1=Grant/research support | 2=Consultant
3=Speaker's bureau | 4=Stock shareholder
5=Other support
Close this window